Multi-Omics Profiling Proves Cost-Effective

Multi-Omics Profiling Proves Cost-Effective: TPC Melanoma Study Published in npj Precision Oncology

A comprehensive cost analysis from the Tumor Profiler melanoma project has been accepted for publication in npj Precision Oncology. The study demonstrates that multi-omics-guided treatment decisions do not lead to significantly higher treatment costs compared to standard care, addressing a key concern in precision oncology implementation.

The manuscript, titled "Comparative cost analysis of a diagnostic multi-omics platform for decision support in advanced cancer – results from the Tumor Profiler Melanoma project," compared healthcare costs between melanoma patients treated with TuPro multi-omics profiling versus those receiving standard next-generation sequencing testing. After statistical adjustment of the cohorts, researchers found no evidence of significant differences in total costs (95% confidence interval -10% to +67%) or treatment costs (95% confidence interval -28% to +41%) between the two groups.

While diagnostic costs for the TuPro platform were higher than standard testing (CHF 17,554 versus CHF 3,058), this difference was offset by comparable treatment costs. The study suggests that in the palliative setting where high-quality evidence for treatment options is scarce, multi-omics-guided treatment decisions may be equally effective but potentially less costly than conventional approaches.

The analysis included 89 TuPro patients with 176 treatment lines and 124 control patients with 182 treatment lines, using inverse probability of treatment weighting to ensure comparability between cohorts. The study was led by Dr Tarun Mehra, Dr Dominik Menges and Prof. Andreas Wicki from the University Hospital Zurich, with contributions from the entire Tumor Profiler Consortium.

"These findings are crucial for demonstrating that precision oncology approaches like the Tumor Profiler can be implemented without dramatically increasing healthcare costs," the authors conclude. "We found no evidence that treatment recommendations guided by advanced multi-omics profiling led to significantly higher treatment costs in a Swiss context."

The study builds on previously published feasibility and effectiveness outcomes from the TuPro melanoma project, which showed a 38% objective response rate in difficult-to-treat palliative patients and significantly improved progression-free survival in third-line treatment compared to matched controls.

Publication details:

Mehra, T., Menges, D., Gosztonyi, B. et al. Comparative cost analysis of a diagnostic multi-omics platform for decision support in advanced cancer – results from the Tumor Profiler Melanoma project. npj Precision Oncology (2025). https://doi.org/10.1038/s41698-025-01229-5

Accepted: 27 November 2025 | Published: 17 December 2025